Glyoxalase Domain-containing Protein 4 (GLOD4), the First Identified in a New Class of Enzymes Called Nitrases, Generates Nitrated ...

The research field of 'cellular IRESes' lay dormant for decades, as there was no uniform standard of reliable methods for the clear characterization of these starting points for the ribosome-mediated ...

"The discovery of a protein with a new type of enzymatic activity that has never before been characterized is a significant scientific accomplishment, and the potential that it is a therapeutic target ...

A recently identified bacterial protein structure is contributing to the design of novel anticancer drug delivery systems.

Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an ...

Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Silent synapses are dormant neural connections that hold untapped brain potential. Discover how ketamine, exercise, and other ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.0, a high estimate of $47.00 ...

a proprietary bifunctional fusion protein combining IL-18BPR and IL-12, which may enhance therapeutic efficacy for cancer patients. Management’s communication about the allowed patent and new ...

In experiments conducted at the University of São Paulo, tumor stem cells became less able to proliferate and invade tissues ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

US biotech Stoke Therapeutics (Nasdaq: STOK), which is dedicated to restoring protein expression by harnessing the body’s ...